Regulation of the dopamine transporter - Addiction Research ...

DAT Regulation Schmitt & Reith
in vivo voltammetric study. J. Neurosci. 22: 6272–
6281.
99. Mason, J.N., H. Farmer, I.D. Tomlinson, et al. 2005.
Novel fluorescence-based approaches for the study of
biogenic amine transporter localization, activity, and
regulation. J. Neurosci. Methods 143: 3–25.
100. Bolan, E.A., B. Kivell, V. Jaligam, et al. 2007. D2 receptors
regulate dopamine transporter function via an extracellular
signal-regulated kinases 1 and 2-dependent
and phosphoinositide 3 kinase-independent mechanism.
Mol. Pharmacol. 71: 1222–1232.
101. Zapata, A., B. Kivell, Y. Han, et al. 2007. Regulation
of dopamine transporter function and cell surface expression
by D3 dopamine receptors. J. Biol. Chem. 282:
35842–35854.
102. Lee, F.J., L. Pei, A. Moszczynska, et al. 2007. Dopamine
transporter cell surface localization facilitated by a direct
interaction with the dopamine D2 receptor. EMBO
J. 26: 2127–2136.
103. Bertolino, A., L. Fazio, A. Di Giorgio, et al. 2009. Genetically
determined interaction between the dopamine
transporter and the D2 receptor on prefronto-striatal
activity and volume in humans. J. Neurosci. 29: 1224–
1234.
104. Borowsky, B., N. Adham, K.A. Jones, et al. 2001. Trace
amines: identification of a family of mammalian G
protein-coupled receptors. Proc. Natl. Acad. Sci. USA
98: 8966–8971.
105. Burchett, S.A. & T.P. Hicks. 2006. The mysterious trace
amines: protean neuromodulators of synaptic transmission
in mammalian brain. Prog. Neurobiol. 79: 223–
246.
106. Bunzow, J.R., M.S. Sonders, S. Arttamangkul,
et al. 2001. Amphetamine, 3,4-methylenedioxymethamphetamine,
lysergic acid diethylamide, and
metabolites of the catecholamine neurotransmitters are
agonists of a rat trace amine receptor. Mol. Pharmacol.
60: 1181–1188.
107. Xie, Z. & G.M. Miller. 2008. Beta-phenylethylamine alters
monoamine transporter function via trace amineassociated
receptor 1: implication for modulatory roles
of trace amines in brain. J. Pharmacol. Exp. Ther. 325:
617–628.
108. Xie, Z., S.V. Westmoreland & G.M. Miller. 2008. Modulation
of monoamine transporters by common biogenic
amines via trace amine-associated receptor 1 and
monoamine autoreceptors in human embryonic kidney
293 cells and brain synaptosomes. J. Pharmacol.
Exp. Ther. 325: 629–640.
109. Jacob, M.S. & D.E. Presti. 2005. Endogenous psy-
choactive tryptamines reconsidered: an anxiolytic role
for dimethyltryptamine. Med. Hypotheses 64: 930–
937.
110. Maisonneuve, I.M., S. Archer & S.D. Glick. 1994.
U50,488, a kappa opioid receptor agonist, attenuates
cocaine-induced increases in extracellular dopamine in
the nucleus accumbens of rats. Neurosci. Lett. 181: 57–
60.
111. Thompson, A.C., A. Zapata, J.B. Justice, et al. 2000.
Kappa-opioid receptor activation modifies dopamine
uptake in the nucleus accumbens and opposes the effects
of cocaine. J. Neurosci. 20: 9333–9340.
112. Shuglin, A. & A. Shuglin. 1991. Phenethylamines I Have
Known and Loved.TransformPress.Berkeley,CA.
113. Nichols, D.E. 2004. Hallucinogens. Pharmacol. Ther.
101: 131–181.
114. Rothman, R.B., M.H. Baumann, C.M. Dersch, et al.
2001. Amphetamine-type central nervous system stimulants
release norepinephrine more potently than they
release dopamine and serotonin. Synapse 39: 32–41.
115. Rothman, R.B. & M.H. Baumann. 2003. Monoamine
transporters and psychostimulant drugs. Eur J. Pharmacol.
479: 23–40.
116. Blough, B.E. 2008. Dopamine-releasing agents. In
Dopamine Transporters: Chemistry, Biology and Pharmacology.
M.L. Trudell & S. Izenwasser, Eds.: 305–318.
Wiley. Hoboken, NJ.
117. Woolverton, W.L., G. Shybut & C.E. Johanson. 1980.
Structure-activity relationships among some d-Nalkylated
amphetamines. Pharmacol. Biochem. Behav.
13: 869–876.
118. Parker, M.A., D. Marona-Lewicka, D. Kurrasch, et
al. 1998. Synthesis and pharmacological evaluation
of ring-methylated derivatives of 3,4-methylenedioxyamphetamine
(MDA). J. Med. Chem. 41: 1001–1005.
119. Setola, V., S.J. Hufeisen, K.J. Grande-Allen, et al. 2003.
3,4-methylenedioxymethamphetamine (MDMA, “Ecstasy”)
induces fenfluramine-like proliferative actions
on human cardiac valvular interstitial cells in vitro. Mol.
Pharmacol. 63: 1223–1229.
120. Baumann, M.H., X. Wang & R.B. Rothman. 2007.
3,4-Methylenedioxymethamphetamine (MDMA) neurotoxicity
in rats: a reappraisal of past and present findings.
Psychopharmacology 189: 407–424.
121. Rothman, R.B., S. Jayanthi, X. Wang, et al. 2003. Highdose
fenfluramine administration decreases serotonin
transporter binding, but not serotonin transporter protein
levels, in rat forebrain. Synapse 50: 233–239.
122. Xie, T., L. Tong, M.W. McLane, et al. 2006. Loss of
serotonin transporter protein after MDMA and other
338 Ann. N.Y. Acad. Sci. 1187 (2010) 316–340 c○ 2010 New York Academy of Sciences.